Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam M Farkas

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Nature Reviews. Immunology|July 22, 2022
XXtra killer cellsAshley Reid Cahn, Adam M Farkas
Journal of Immunology (Baltimore, Md. : 1950)|December 17, 2013
Novel mechanisms underlying the immediate and transient global tolerization of splenic dendritic cells after vaccination with a self-antigenAdam M Farkas, Olivera J Finn
Immunity|July 23, 2015
Escaping Negative Selection: ILC You in the GutAdam M Farkas, Ivaylo I Ivanov
Seminars in Immunology|April 21, 2010
Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulationAdam M Farkas, Olivera J Finn
Journal of Immunology (Baltimore, Md. : 1950)|February 20, 2013
Antigen choice determines vaccine-induced generation of immunogenic versus tolerogenic dendritic cells that are marked by differential expression of pancreatic enzymesAdam M Farkas, Douglas M Marvel, Olivera J Finn
Current Opinion in Investigational Drugs (London, England : 2000)|December 7, 2007
Detecting DNA: getting and begetting cancerAdam M Farkas, Tina M Kilgore, Michael T Lotze
The Urologic Clinics of North America|October 3, 2020
Harnessing Natural Killer Cell Function for Genitourinary CancersNina Bhardwaj, Adam M Farkas, Zeynep Gul, et al.
Oncotarget|September 28, 2013
Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migrationSandra Cascio, Adam M Farkas, Rebecca P Hughey, et al.
World Journal of Urology|June 4, 2018
Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancerFrançois Audenet, Adam M Farkas, Harry Anastos, et al.
Urologic Oncology|July 16, 2020
TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancerKyrollis Attalla, Adam M Farkas, Harry Anastos, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Nature Reviews. Immunology|July 22, 2022
XXtra killer cellsAshley Reid Cahn, Adam M Farkas
Journal of Immunology (Baltimore, Md. : 1950)|December 17, 2013
Novel mechanisms underlying the immediate and transient global tolerization of splenic dendritic cells after vaccination with a self-antigenAdam M Farkas, Olivera J Finn
Immunity|July 23, 2015
Escaping Negative Selection: ILC You in the GutAdam M Farkas, Ivaylo I Ivanov
Seminars in Immunology|April 21, 2010
Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulationAdam M Farkas, Olivera J Finn
Journal of Immunology (Baltimore, Md. : 1950)|February 20, 2013
Antigen choice determines vaccine-induced generation of immunogenic versus tolerogenic dendritic cells that are marked by differential expression of pancreatic enzymesAdam M Farkas, Douglas M Marvel, Olivera J Finn
Current Opinion in Investigational Drugs (London, England : 2000)|December 7, 2007
Detecting DNA: getting and begetting cancerAdam M Farkas, Tina M Kilgore, Michael T Lotze
The Urologic Clinics of North America|October 3, 2020
Harnessing Natural Killer Cell Function for Genitourinary CancersNina Bhardwaj, Adam M Farkas, Zeynep Gul, et al.
Oncotarget|September 28, 2013
Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migrationSandra Cascio, Adam M Farkas, Rebecca P Hughey, et al.
World Journal of Urology|June 4, 2018
Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancerFrançois Audenet, Adam M Farkas, Harry Anastos, et al.
Urologic Oncology|July 16, 2020
TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancerKyrollis Attalla, Adam M Farkas, Harry Anastos, et al.
Pageof 3